GlassScriptPhysician profile
Gene R Fuller
NPI 1396710281
$5,170.46
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $612 · 2021: $952 · 2022: $1,207 · 2023: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.10 | 2019-2023 | |
| Amgen INC. | $422.76 | 2019-2023 | Evenity, Prolia, Tezspire |
| Pfizer INC. | $368.79 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $354.21 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.46 | 2019-2023 | Spiriva Respimat, Synjardy, Jardiance |
| Lilly USA, LLC | $301.40 | 2020-2023 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $272.63 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $261.11 | 2019-2023 | Breztri |
| Glaxosmithkline, LLC. | $237.60 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Janssen Pharmaceuticals, INC | $162.43 | 2019-2022 | |
| Lucid Diagnostics INC. | $158.05 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $143.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $133.11 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Antares Pharma, INC. | $121.16 | 2019-2020 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.